++ Jetzt auf das Wachstumspotenzial alternativer Energieträger inkl. strenger ESG-Kriterien setzen - mit dem UC ESG Global Renewable Energies Index! ++-w-
24.05.2022 22:59

Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis

Folgen
Werbung
Tuesday, May 24, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>> Bank of America shares have declined -14.6% over the past year against the Zacks Banks - Major Regional industry’s decline of -16.6%. However, the company’s first-quarter 2022 results benefited substantially from loan growth and higher rates. The Zacks analyst believes that the opening of financial centers, enhancement in digital capabilities and cost-saving efforts will likely keep aiding profits. Supported by robust loan growth and the investment banking (IB) pipeline, the company’s top line is expected to keep improving.Bank of America is expected to keep enhancing shareholder value through impressive capital deployments. However, despite the expected rate hikes in 2022, relatively low rates might hurt margins and interest income for some time in the near term. The volatile nature of the trading business is concerning as it might hamper fee income growth. (You can read the full research report on Bank of America here >>>) Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+34.2% vs. +20.0%) on the back of one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to further boost sales.However, lower realized prices in the Unites States, loss of exclusivity for products and stiff competition are affecting sales. Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy have hurt the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio is concerning too. (You can read the full research report on Novo Nordisk here >>>) Novartis shares have gained +3.7% in the year to date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +5.1%. Novartis’ performance in the first quarter, in fact, was good as the lagging Sandoz business returned to growth and cardiovascular drug Entresto maintained its stellar performance.The Zacks analyst believes that drugs like Cosentyx, Entresto, Kesimpta, gene therapy Zolgensma, Kisqali and Leqvio should continue to fuel growth and offset the impact of generic competition. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and the label expansion of key drugs should also aid performance. However, generic competition for key drugs and pipeline setbacks poses concerns. (You can read the full research report on Novartis here >>>) Other noteworthy reports we are featuring today include Petróleo Brasileiro S.A. - Petrobras (PBR), Analog Devices, Inc. (ADI), and Sony Group Corp. (SONY). Mark VickerySenior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must ReadLoans, Cost Management Aid BofA (BAC) Amid Fee Income WoesNovo Nordisk's (NVO) Diabetes Drugs Aid Growth Amid RivalryNew Drugs Fuel Novartis (NVS), Generic Competition A HeadwindFeatured ReportsClean Assets, North America Focus Aid Clearway Energy (CWEN)Per the Zacks analyst Clearway Energy is gaining by generating electricity from renewable energy sources to meet rising demand and focus on domestic market saves it from currency risks.SONY to Gain from Brand Focus & Improving G&NS Segment SalesPer the Zacks analyst, Sony's focus on the premium segment of the branded products market to boost growth is a tailwind. The company expects G&NS Segment sales to be driven by higher hardware sales. Strategic Alliances Aid Omnicell (OMCL), Weak Margins AilThe Zacks analyst is optimistic about Omnicell's long-term sole source agreements with top U.S. health systems. Yet, contraction of both margins on escalating operating costs does not bode well.Boyd Gaming (BYD) Banks on Expansion Efforts, Costs HighPer the Zacks analyst, Boyd Gaming is likely to benefit from its interactive gaming platform, FanDuel Group partnership and portfolio expansion.Travelers' (TRV) Auto & Homeowners Aids, Cat Loss HurtsPer the Zacks analyst, persistent progress and strong market of the auto and homeowners businesses contribute to revenue growth of the company. However, exposure to catastrophe loss remains a headwindLoan Growth Supports U.S. Bancorp (USB) Despite Higher CostsThe Zacks analyst believes that a solid business model and initiatives to expand market share have helped U.S. Bancorp witness growth in loans and deposits.EOG Resources (EOG) Banks on Delaware & Bakken Shale PlaysPer the Zacks analyst, EOG Resources' strong footprint in oil-rich Delaware and Bakken shale plays has made the firm's production outlook bright. However, rising lease & well expenses are concerning.New UpgradesGATX Rides on Railcar Leasing Market & Pro-Investor Steps The Zacks analyst is optimistic about GATX's impressive record with respect to dividends and buybacks. Moreover, a gradual improvement in the North American railcar leasing market is a bonus.Petrobras (PBR) Aided by Brazil's Pre-Salt Oil ReservesThe Zacks analyst believes that Petrobras' stake in Brazil's huge pre-salt oil reserves puts it in an enviable position to maintain an impressive production growth profile for years to come.BMS Solutions & Solid Radio Systems Aid Analog Devices (ADI)Per the Zacks analyst, Analog Devices is riding on growing momentum of Battery Management System solutions in electric vehicles and solid adoption of advanced radio systems in 5G infrastructure.New DowngradesChip Scarcity & High Commodity Costs to Hurt Winnebago (WGO)The Zacks analyst is of the view that microchip shortage and scarcity of various RV components may weigh on Winnebago's sales. Rising prices of raw materials would further dent margins.Kohl's (KSS) Hurt by Product Cost Inflation, SG&A ExpensesPer the Zacks analyst, Kohl's gross margin remains troubled by product and freight cost headwinds. Also, increased growth investments and wage costs among other factors are likely to raise SG&A costs.Universal Health's (UHS) Margins Hurt by High Operating CostsPer the Zacks Analyst, higher operating expenses continue to put pressure on the company's margins. Rise in COVID-19 patient volumes are hampering patient volumes in behavioral health care facilities.Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bank of America Corporation (BAC): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Analog Devices, Inc. (ADI): Free Stock Analysis Report Petroleo Brasileiro S.A. Petrobras (PBR): Free Stock Analysis Report Novo Nordisk AS (NVO): Free Stock Analysis Report Sony Corporation (SONY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf Bank of America Corp.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Bank of America Corp.
Long
Short
Hebel wählen:
5x
10x
Name
Hebel
KO
Emittent
Quelle: Zacks

Nachrichten zu Novartis AG

  • Relevant
  • Alle
    1
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Novartis AG

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
22.06.2022Novartis NeutralUBS AG
22.06.2022Novartis UnderweightJP Morgan Chase & Co.
22.06.2022Novartis SellDeutsche Bank AG
27.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
27.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.05.2022Novartis BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
28.04.2022Novartis Conviction Buy ListGoldman Sachs Group Inc.
26.04.2022Novartis BuyJefferies & Company Inc.
19.04.2022Novartis BuyJefferies & Company Inc.
22.06.2022Novartis NeutralUBS AG
27.04.2022Novartis NeutralCredit Suisse Group
27.04.2022Novartis NeutralUBS AG
26.04.2022Novartis NeutralUBS AG
08.04.2022Novartis NeutralUBS AG
22.06.2022Novartis UnderweightJP Morgan Chase & Co.
22.06.2022Novartis SellDeutsche Bank AG
27.04.2022Novartis UnderweightJP Morgan Chase & Co.
27.04.2022Novartis SellDeutsche Bank AG
26.04.2022Novartis UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Ukraine-Krieg im Ticker: DAX schließt fester - unter 13.200 Punkten -- Nordex beschafft frisches Kapital -- Neue Daten zu Omikron-Impfstoffen von BioNTech & Co. -- Coinbase, Singulus, Bayer im Fokus

McDonald's mit neuem Finanzvorstand. Normalisierung des Flugbetriebs erst 2023 erwartet - Lufthansa reaktiviert den A380. Sparkassenverband tritt bei Bitcoin-Handel auf die Bremse. EssilorLuxottica-Chairman Leonardo Del Vecchio verstorben. Prosus will Bewertungsabschlag durch unbefristeten Aktienrückkauf mindern. Intesa Sanpaolo kauft ab 4. Juli eigene Aktien zurück.

Umfrage

Goldpreis im Fokus der Anleger: Sind Sie in Gold investiert?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln